File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
  • Basic View
  • Metadata View
  • XML View
TitleHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
 
AuthorsPan, CQ6
Tong, M9
Kowdley, KV10
Hu, K2
Chang, T8
Lai, C7
Yoon, SK1
Lee, SS3
Cohen, D5
Tang, H5
Tsai, N4
 
KeywordsAntiviral Therapy
Hepatitis B Virus
Nucleos(T)Ide Analogue
 
Issue Date2012
 
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
 
CitationClinical Gastroenterology And Hepatology, 2012 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.cgh.2012.03.016
 
AbstractThere are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute.
 
ISSN1542-3565
2012 Impact Factor: 6.648
2012 SCImago Journal Rankings: 1.670
 
DOIhttp://dx.doi.org/10.1016/j.cgh.2012.03.016
 
DC FieldValue
dc.contributor.authorPan, CQ
 
dc.contributor.authorTong, M
 
dc.contributor.authorKowdley, KV
 
dc.contributor.authorHu, K
 
dc.contributor.authorChang, T
 
dc.contributor.authorLai, C
 
dc.contributor.authorYoon, SK
 
dc.contributor.authorLee, SS
 
dc.contributor.authorCohen, D
 
dc.contributor.authorTang, H
 
dc.contributor.authorTsai, N
 
dc.date.accessioned2012-09-05T05:32:07Z
 
dc.date.available2012-09-05T05:32:07Z
 
dc.date.issued2012
 
dc.description.abstractThere are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationClinical Gastroenterology And Hepatology, 2012 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.cgh.2012.03.016
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.cgh.2012.03.016
 
dc.identifier.hkuros208887
 
dc.identifier.issn1542-3565
2012 Impact Factor: 6.648
2012 SCImago Journal Rankings: 1.670
 
dc.identifier.pmid22475742
 
dc.identifier.scopuseid_2-s2.0-84865319280
 
dc.identifier.urihttp://hdl.handle.net/10722/163490
 
dc.languageeng
 
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
 
dc.publisher.placeUnited States
 
dc.relation.ispartofClinical Gastroenterology and Hepatology
 
dc.subjectAntiviral Therapy
 
dc.subjectHepatitis B Virus
 
dc.subjectNucleos(T)Ide Analogue
 
dc.titleHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Pan, CQ</contributor.author>
<contributor.author>Tong, M</contributor.author>
<contributor.author>Kowdley, KV</contributor.author>
<contributor.author>Hu, K</contributor.author>
<contributor.author>Chang, T</contributor.author>
<contributor.author>Lai, C</contributor.author>
<contributor.author>Yoon, SK</contributor.author>
<contributor.author>Lee, SS</contributor.author>
<contributor.author>Cohen, D</contributor.author>
<contributor.author>Tang, H</contributor.author>
<contributor.author>Tsai, N</contributor.author>
<date.accessioned>2012-09-05T05:32:07Z</date.accessioned>
<date.available>2012-09-05T05:32:07Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Clinical Gastroenterology And Hepatology, 2012</identifier.citation>
<identifier.issn>1542-3565</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/163490</identifier.uri>
<description.abstract>There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA &lt;300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. &#169; 2012 AGA Institute.</description.abstract>
<language>eng</language>
<publisher>WB Saunders Co. The Journal&apos;s web site is located at http://www.elsevier.com/locate/cgh</publisher>
<relation.ispartof>Clinical Gastroenterology and Hepatology</relation.ispartof>
<subject>Antiviral Therapy</subject>
<subject>Hepatitis B Virus</subject>
<subject>Nucleos(T)Ide Analogue</subject>
<title>High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.cgh.2012.03.016</identifier.doi>
<identifier.pmid>22475742</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84865319280</identifier.scopus>
<identifier.hkuros>208887</identifier.hkuros>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The Catholic University of Korea
  2. UCI Medical Center
  3. University of Calgary
  4. University of Hawaii at Manoa
  5. Bristol-Myers Squibb
  6. Mount Sinai School of Medicine
  7. Queen Mary Hospital Hong Kong
  8. National Cheng Kung University
  9. University of California, Los Angeles
  10. Virginia Mason Medical Center